This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ADRO Aduro Biotech (ADRO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aduro Biotech Stock (NASDAQ:ADRO) 30 days 90 days 365 days Advanced Chart Get Aduro Biotech alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.28▼$14.6052-Week Range N/AVolume171,500 shsAverage Volume162,237 shsMarket Capitalization$236.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. Read More Receive ADRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address ADRO Stock News HeadlinesAduro Clean Technologies Engages Global Leader Zeton for Design and Fabrication of Hydrochemolytic™ Pilot PlantNovember 19, 2024 | markets.businessinsider.comAduro Clean Technologies Inc.August 29, 2024 | wsj.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 2 at 2:00 AM | Timothy Sykes (Ad)ACTHD Aduro Clean Technologies Inc.August 25, 2024 | seekingalpha.comBiotech’s Zandy Forbes: My lost family fortune and being the first to earn a livingMay 4, 2024 | thetimes.co.ukTAduro Clean Technologies Inc Ordinary SharesFebruary 24, 2024 | morningstar.comMPT Adaro Energy Indonesia TbkJanuary 3, 2024 | morningstar.comMPT Adaro Energy Indonesia Tbk ADRODecember 2, 2023 | morningstar.comMSee More Headlines ADRO Stock Analysis - Frequently Asked Questions How were Aduro Biotech's earnings last quarter? Aduro Biotech, Inc. (NASDAQ:ADRO) announced its quarterly earnings data on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to analysts' expectations of $8.81 million. Aduro Biotech had a negative net margin of 230.92% and a negative trailing twelve-month return on equity of 101.73%. When did Aduro Biotech IPO? Aduro Biotech (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What other stocks do shareholders of Aduro Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV) and Amarin (AMRN). Company Calendar Last Earnings5/04/2020Today7/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADRO CIK1435049 Webwww.aduro.com Phone(206) 485-7051FaxN/AEmployees152Year FoundedN/AProfitability EPS (Trailing Twelve Months)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.37 million Net Margins-230.92% Pretax MarginN/A Return on Equity-101.73% Return on Assets-22.35% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual Sales$17.26 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / BookN/AMiscellaneous Outstanding Shares16,212,000Free FloatN/AMarket Cap$236.61 million OptionableOptionable Beta0.40 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ADRO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aduro Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aduro Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.